Selling a healthcare company is a daunting task that requires significant foresight, planning and expertise in addition to the tremendous amount of time required to consummate a deal. For a first time seller, the process is especially intimidating as the
investment bank
A Perspective From the Inside: An Interview with Trey Crabb of Health Strategy Partners
By Amber Walsh on
Posted in Life Sciences Investing
I recently had the pleasure of interviewing Trey Crabb, Founder and President of Health Strategy Partners, LLC, located in Nashville. Trey is a veteran strategic and financial advisor to the healthcare industry. In 2010, Trey founded Health Strategy Partners after…
A Courting Process Part III: Still More Thoughts on Selecting an Investment Bank That is Right for You
By Amber Walsh on
In two prior posts regarding, we addressed various questions for a seller to consider when selecting an investment bank to help the seller achieve its transaction goals. Those questions, as well as those below, are just a handful of questions…
A Courting Process Part II: Additional Thoughts re Selecting the Investment Bank That is Right for You
By Amber Walsh on
As a follow-up to our prior post on the topic, below are a few key additional questions that sellers can consider when evaluating investment banks in order to find the bank that will ultimately meet the sellers’ needs. These questions are excerpted…
A Courting Process Part I: Selecting the Investment Bank That is Right for You
By Amber Walsh on
Posted in Healthcare Services Investing
For many healthcare companies, when it is time to sell or refinance their business, finding an investment bank that fits the needs, philosophies and goals of the seller can be an important component for success during the sale/refinance process. Earlier this year…
Continue Reading A Courting Process Part I: Selecting the Investment Bank That is Right for You
Biopharmaceutical Companies Cephalon and Ception Merge; Choice in Investment Bank One Key Component of Deal Success
By Amber Walsh on
Posted in Life Sciences Investing
On April 6th, US-based biopharmaceutical company Cephalon, Inc. (NASDAQ: CEPH) acquired all of the outstanding capital stock of Ception Therapeutics, Inc., also a US-based biopharmaceutical company focused on developing novel products to address areas of unmet medical …